Be part of the knowledge.™

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

852

LikeLikedUnlike

16-30 of 137

MinuteCE®
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 credits 5 episodes
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credits
CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credits
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credits
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credits
advertisement
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
November 9, 2026
0.75 credits
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
- Neal Ready, MD, PhD
0.50 program credits
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
- Ticiana Leal, MD
0.50 program credits
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
- Ticiana Leal, MD
0.50 program credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
MinuteCE®
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
- Neal Ready, MD, PhD
0.50 program credits
advertisement
MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes
The Evidence Base: Key Trials and Emerging Data
MinuteCE®
The Evidence Base: Key Trials and Emerging Data
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended